Program
gemcitabine-oxaliplatin regimen
Also written as “TQB2825 injection + GemOx”, “GEMOX [gemcitabine+oxaliplatin]” and “Gemcitabine-Oxaliplatin”.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Antengene | 10 open or running | phase 2since May 25, 2020 | May 25, 2020 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 2since Jun 28, 2021 | Jun 28, 2021 | none ahead |
| Sanofi | 10 open or running | phase 3since Jul 13, 2004 | Jul 13, 2004 | none ahead |
| Sino Biopharmaceutical | 11 open or running | phase 2since Feb 12, 2025 | Feb 12, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2004First study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to SanofiSanofi · NCT00087802 · 383 enrolled · United States
- May 25, 2020Antengene’s first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to AntengeneAntengene · NCT04425070 · 56 enrolled · China
- Jun 28, 2021Jiangsu HengRui Medicine’s first study: phase 2 study in RecurrenceNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04948788 · 102 enrolled · China
- Feb 12, 2025Sino Biopharmaceutical’s first study: phase 2 study in Lymphoma, Large B-Cell, DiffuseNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06829771 · 90 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06829771Lymphoma, Large B-Cell, Diffuse · China | 2 | Recruiting | Sino Biopharmaceutical | May 2026 | 90 |
| NCT04948788Recurrence · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Apr 2023 | 102 |
| NCT04425070Lymphoma, T-Cell, Peripheral · China | 2 | Terminated | Antengene | Dec 30, 2025 | 56 |
| NCT00087802Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | Sanofi | May 2007 | 383 |
How it is read
Names in the registry
- “TQB2825 injection + GemOx”, 1 entry
- “GEMOX [gemcitabine+oxaliplatin]”, 1 entry
- “Gemcitabine-Oxaliplatin”, 1 entry
- “gemcitabine/Eloxatin (GEMOX)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Lymphoma, T-Cell, Peripheral, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.